Publicacions en col·laboració amb investigadors/es de Hospital Universitario Marqués de Valdecilla (14)

2023

  1. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study)

    Mycoses, Vol. 64, Núm. 11, pp. 1334-1345

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  3. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

    American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687

2014

  1. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011

    Eurosurveillance, Vol. 19, Núm. 20

2012

  1. Long-term benefits of nevirapine-containing regimens: Multicenter study with 506 patients, followed-up a median of 9 years

    Current HIV Research, Vol. 10, Núm. 6, pp. 513-520

2009

  1. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2007

  1. Recomendaciones españolas sobre el uso adecuado de enfuvirtida

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 2, pp. 131-142

2005

  1. Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study

    Current Therapeutic Research - Clinical and Experimental, Vol. 66, Núm. 2, pp. 117-129